Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-02-08
2005-02-08
Criares, Theodore J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S594000, C514S595000, C514S596000, C424S646000, C424S655000
Reexamination Certificate
active
06852760
ABSTRACT:
Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.
REFERENCES:
patent: 4921877 (1990-05-01), Cashmere et al.
patent: 4959222 (1990-09-01), Nadland et al.
patent: 5013752 (1991-05-01), Dobbins
patent: 5045316 (1991-09-01), Kaplan
patent: 5069913 (1991-12-01), Posner et al.
patent: 5087623 (1992-02-01), Boynton et al.
patent: 5087624 (1992-02-01), Boynton et al.
patent: RE33988 (1992-07-01), Evans
patent: 5164384 (1992-11-01), Paul
patent: 5215750 (1993-06-01), Keane, II
patent: 5266560 (1993-11-01), Furman et al.
patent: 5300496 (1994-04-01), McNeill et al.
patent: 5308627 (1994-05-01), Umbdenstock, Jr.
patent: 5332579 (1994-07-01), Umbdenstock
patent: 5496827 (1996-03-01), Patrick
patent: 5527790 (1996-06-01), McNeill et al.
patent: 5532269 (1996-07-01), Koltringer
patent: 5543405 (1996-08-01), Keown
patent: 5550113 (1996-08-01), Mann
patent: 5597585 (1997-01-01), Williams et al.
patent: 5599835 (1997-02-01), Fisher
patent: 5614224 (1997-03-01), Womack
patent: 5620967 (1997-04-01), McNeill et al.
patent: 5635535 (1997-06-01), Wagstaff
patent: 5637324 (1997-06-01), Bland
patent: 5641531 (1997-06-01), Liebrecht et al.
patent: 5654011 (1997-08-01), Jackson et al.
patent: 5665385 (1997-09-01), Johnson et al.
patent: 5707980 (1998-01-01), Knutson et al.
patent: 5730988 (1998-03-01), Womack
patent: 5763484 (1998-06-01), Horrobin
patent: 5770215 (1998-06-01), Moshyedi
patent: 5789401 (1998-08-01), McCarty
patent: 5807586 (1998-09-01), Jackson et al.
patent: 5817329 (1998-10-01), Gardiner
patent: 5849338 (1998-12-01), Richardson et al.
patent: 5866563 (1999-02-01), McNeil et al.
patent: 5871769 (1999-02-01), Fleming et al.
patent: 5885980 (1999-03-01), Gutierrez et al.
patent: 5905075 (1999-05-01), Harpe et al.
patent: 5908647 (1999-06-01), Golightly et al.
patent: 5962030 (1999-10-01), Fine
patent: 5980905 (1999-11-01), De La Harpe et al.
patent: 6203819 (2001-03-01), Fine
patent: 6376549 (2002-04-01), Fine et al.
patent: 298 05 782 (1998-09-01), None
patent: 561 744 (1993-09-01), None
patent: 0 834 318 (1998-04-01), None
patent: WO 9111117 (1991-08-01), None
patent: WO 9625939 (1996-08-01), None
patent: WO 9635421 (1996-11-01), None
patent: WO 9639871 (1996-12-01), None
patent: WO 9711614 (1997-04-01), None
patent: WO 9804248 (1998-02-01), None
patent: WO 9841113 (1998-09-01), None
patent: WO 9842211 (1998-10-01), None
patent: WO 9907387 (1999-02-01), None
patent: WO 0012095 (2000-03-01), None
Abbott et al., “The Impact of Diabetes on Survival Following Myocardial Infarction in Men vs Women,” JAMA, 260(23):3456-3460 (1988).
ACC/AHA Task Force Report, “Guidelines for the Early Management of Patients with Acute Myocardial Infarction; a Report of the American College of Cardiology/ American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascualr Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction),” JACC, 16(2):249-292 (1990).
Aharon et al., “Vanadul Sulfate Does Not Enhance Insulin Action in Patients with Type I Diabetes,” Diabetes Care, 21:2194-2195 (1998).
American Diabetes Association: “Nutrition Recommendations and Principles for People with Diabetes Mellitus,” Diabetes Care, 19(1):S16-S19 (1996).
American Diabetes Association: “Nutrition Recommendations and Principles for People with Diabetes Mellitus,” DiabetesCare, 20(1):S14-S17 (1997).
Amoikon, et al., “Effect of chromium tripicolinate on growth, glucose tolerance, insulin sensitivity, plasma metabolites, and growth hormone in pigs,” J. Anim. Sic. (1995) 73(4) 1123-30 XP000901969 Abstract.
Anderson and Kozlovsky, “Chromium Intake, Absorption and Execretion of Subjects Consuming Self-Selected Diets,” The American Journal of Clinical Nutrition, 41:1177-1183 (1985).
Anderson et al., “Elevated Intakes of Supplemental Chromium Improve Glucose and Insulin Varibles in Individuals With Type 2 Diabetes”, Diabetes 46:1786-1791 (1997).
Anderson et al., Urinary Chromium Execretion and Insulinogenic Properties of Carbohydrates,: Am J Clin Nutr, 51:864-868 (1990).
Anderson, Richard “Chromium, Glucose Intolerance and Diabetes,” The American Journal of Clinical Nutrition, vol. 17, No. 6 548-555 (1998).
Antiplatelet Trialists' Collaboration, “Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients,” BMJ 308:81-106 (1994).
Arsenian, M.A., “Magnesium and Cardiovascular Disease,” Progress in Cardiovascular Disease 35(4):271-310 (1993).
Arsenian, M.A., “Magnesium and Autonomic Nervous System, ” Magnesium and Cardiovascular Disease 291-310 (1993).
Avins, “Lowering Risk without Lowering Cholesteral: Implications of National Cholesterol Policy” Annals of Internal Medicine 125 (6):502-506 (1996).
Bailey, C.J., “Biguanides and NIDDM” Diabetes Care 15 (6):755-772 (1992).
Barnard, et al., “Diet and Exercise in Treatment of NIDDM; The need for early emphasis” Diabetes Care 17 (12):1469-1472 (1994).
Bayraktar, M., “A Comparison of Acarbose Versus Metformin as an Adjuvant Therapy in Sulfonylurea-Treated NIDDM Patients” Diabetes Care 19 (3):252-254 (1996).
Bierman, E.L., “Atherogenesis in diabetes” Arteriosclerosis and Thrombosis 12 (6):647-656 (1992).
Bloomgarden, A.T., “American Diabetes Association Scientific Sessions, 1995; Magnesium Deficiency, Atherosclerosis, and Health Care” Diabetes Care 18 (12):1623-1627 (1995).
Boyd et al., “Combined dietary chromium picolinate supplementation and an exercise program leads to a reduction of serum cholesterol and insulin in college-aged subjects,” J. Nutr. Biochem. (1998) 9(8), 471-475 XP000901922 Abstract.
Caballero, “Vitamin E Improves the Action of Insulin” Nutrition Reviews 51 (11):339-340 (1993).
Calle-Pascual, A.L., “Comparison Between Acarbose, Metformin, and Insulin Treatment in Type 2 Diabetic Patients with Secondary Failure to Sulfonylurea Treatment” Diabete & Metabolisme (Paris) 21:256-260 (1995).
Cam et al., “Long—term effectiveness of oral vanadyl sulphate in streptozotocin-diabetic rats”, Diabetologia 36: 218-224 (1993).
Cefalu, et al, “Effect of Chromium Picolinate on Insulin Sensitivity In Vivo”, The Journal of Trace Elements in Experimental Medicine 12:71-83 (1999).
Cerulli et al., “Chromium Picolinate Toxicity”, The Annals of Pharmacotherapy 32:428-431, ( Apr. 1998).
Cheng, et al, “Follow-up Survey of People in China with Type 2 Diabetes Mellitus Consuming Supplemental Chromium,” The Journal of Trace Elements in Experimental Medicine 12:55-60 (1999).
Chowdhury and Lasker, “Elevated glycated haemoglobin in non-diabetic patients is associated with an increased mortality in myocardial infarction”, Postgrad. Med. J. 74: 480-481 (1998).
Clarke, R. J., “Suppression of Thromboxane A2but not of Systemic Prostacyclin by Controlled-Release Aspirin” The New England Journal of Medicine 325 (16):1137-1141 (1991).
Classen, H. G., “Magnesium and Potassium Deprivation and Supplementation in Animals and Man: Aspects in View of Intestinal Absorption” Magnesium 3:257-264 (1984).
Cohen and Kitzes, “Magnesium Sulfate and Digitalis-Toxic Arrhythmias” JAMA 249 (20):2808-2810 (1983).
Cohen, et al., Oral Vanadyl Sulfate Improves Hepatic and Peripheral Insulin Sensitivity in Patients with Non-Insulin-dependent Diabetes Mellitus J. Clin. Invest. 95:2501-2509 (1995).
Colwell et al., “Correlation of Platelet Aggretation, Plasma Factor Activity, and Megathrombocytes in Diabetic Subjects Wi
Fine Stuart A.
Kinsella Kevin J.
Akesis Pharmaceuticals, Inc.
Criares Theodore J.
Foley & Hoag LLP
Gordon Dana M.
LandOfFree
Compositions and methods for treatment for glucose... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treatment for glucose..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment for glucose... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3498207